Hemispherian

Executive Summary

Hemispherian is a private Norwegian biotechnology company founded in 2015, focused on developing next-generation epigenetic cancer therapies. The company's pipeline targets key epigenetic regulators to reprogram cancer cells and improve patient outcomes. Currently in Phase 1 clinical development, Hemispherian leverages its proprietary platform to advance small molecule inhibitors designed for solid and hematologic malignancies. While specific pipeline details are not publicly disclosed, the company's approach aligns with the growing interest in epigenetic modulation as a promising avenue for cancer treatment. With a lean operation based in Oslo, Hemispherian represents an early-stage opportunity in precision oncology, pending clinical validation of its lead candidate.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim data readout for lead epigenetic inhibitor25% success
• Q4 2026Series B financing round to support Phase 2 expansion40% success
• TBDResearch collaboration or licensing deal with larger pharma15% success